GLP1R and type 2 diabetes mellitus: The GLP-1 RAs in people with obesity or type 2 diabetes are associated with a significant reduction in all-cause death, alongside an increased risk of pancreatic adverse events—particularly acute pancreatitis—most pronounced during the first 6 months of treatment.